Aethlon Medical (NASDAQ:AEMD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Aethlon Medical (NASDAQ:AEMD) to a sell rating in a report released on Saturday,Wall Street Zen reports.

Several other equities research analysts have also recently weighed in on AEMD. HC Wainwright reissued a “neutral” rating on shares of Aethlon Medical in a research report on Friday, September 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a research note on Thursday. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Aethlon Medical currently has an average rating of “Reduce” and a consensus target price of $1.50.

Aethlon Medical Stock Performance

Shares of NASDAQ:AEMD opened at $5.16 on Friday. The business has a 50 day moving average price of $4.03 and a 200 day moving average price of $6.66. Aethlon Medical has a twelve month low of $1.41 and a twelve month high of $29.45.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings results on Thursday, August 13th. The medical equipment provider reported ($4.02) EPS for the quarter, missing the consensus estimate of ($3.92) by ($0.10). Research analysts forecast that Aethlon Medical will post -5.74 EPS for the current fiscal year.

Aethlon Medical Company Profile

Aethlon Medical, Inc is a medical technology company focused on developing extracorporeal filtration systems designed to remove harmful biological materials from the blood. The company’s primary technology is the Hemopurifier, an investigational device intended to capture disease-related particles, including exosomes and certain viruses, during blood filtration.

The Hemopurifier is being studied for potential applications in oncology and infectious disease. In cancer research, the device is designed to remove tumor-derived exosomes, which may contribute to immune suppression and disease progression.